Reviva Pharmaceuticals Holdings Stock Current Valuation
| RVPHW Stock | USD 0.22 0.01 4.35% |
Valuation analysis of Reviva Pharmaceuticals helps investors to measure Reviva Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to climb to about 104.2 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (0.000003) in 2024.
Overvalued
Today
Please note that Reviva Pharmaceuticals' price fluctuation is out of control at this time. Calculation of the real value of Reviva Pharmaceuticals is based on 3 months time horizon. Increasing Reviva Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Reviva stock is determined by what a typical buyer is willing to pay for full or partial control of Reviva Pharmaceuticals Holdings. Since Reviva Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Reviva Stock. However, Reviva Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.22 | Real 0.17 | Hype 0.2 |
The intrinsic value of Reviva Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Reviva Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Reviva Pharmaceuticals Holdings helps investors to forecast how Reviva stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Reviva Pharmaceuticals more accurately as focusing exclusively on Reviva Pharmaceuticals' fundamentals will not take into account other important factors: Reviva Pharmaceuticals Holdings Company Current Valuation Analysis
Reviva Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Reviva Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Reviva Pharmaceuticals is extremely important. It helps to project a fair market value of Reviva Stock properly, considering its historical fundamentals such as Current Valuation. Since Reviva Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Reviva Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Reviva Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Reviva Current Valuation Historical Pattern
Today, most investors in Reviva Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Reviva Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Reviva Pharmaceuticals current valuation as a starting point in their analysis.
Reviva Pharmaceuticals Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Reviva Pharmaceuticals Holdings has a Current Valuation of 0.0. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Reviva Pharmaceuticals Holdings is currently under evaluation in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 65.29 Million. Reviva Pharmaceuticals adds roughly 0.0 in current valuation claiming only tiny portion of equities under Health Care industry.Reviva Fundamentals
| Return On Equity | -17.95 | ||||
| Return On Asset | -2.34 | ||||
| Number Of Shares Shorted | 14.36 K | ||||
| EBITDA | (39.5 T) | ||||
| Net Income | (39.26 M) | ||||
| Cash And Equivalents | 353.26 K | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 17.98 M | ||||
| Current Ratio | 0.03 X | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | (28.32 M) | ||||
| Number Of Employees | 15 | ||||
| Beta | -0.055 | ||||
| Market Capitalization | 85.81 M | ||||
| Total Asset | 23.7 M | ||||
| Retained Earnings | (134.35 M) | ||||
| Working Capital | 6.53 M | ||||
| Net Asset | 23.7 M |
About Reviva Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Reviva Pharmaceuticals Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reviva Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reviva Pharmaceuticals Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Reviva Stock Analysis
When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.